SIA
BCRX icon

Sit Investment Associates’s BioCryst Pharmaceuticals BCRX Stock Holding History

Sit Investment Associates’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-150,175
Closed -$1.55M – 476
2015
Q4 		$1.55M Buy
150,175
+8,650
+6% +$86K 0.03% 274
2015
Q3 		$1.61M Buy
141,525
+20,850
+17% +$278K 0.03% 273
2015
Q2 		$1.8M Hold
120,675
– – 0.03% 254
2015
Q1 		$1.09M Buy
120,675
+16,150
+15% +$167K 0.02% 296
2014
Q4 		$1.27M Buy
+104,525
New +$1.15M 0.02% 305

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sit Investment Associates's BCRX Position: Q1 2016 in Review

Sit Investment Associates sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2016, closing a stake of 150,175 shares — an estimated $1.55M sold.

Sit Investment Associates first reported a position in BCRX in Q4 2014 and held it in 5 quarters. The position peaked at $1.8M in Q2 2015. 109 funds tracked by Wall St. Rank hold BCRX as of Q1 2016.

  • Sit Investment Associates reported no remaining BioCryst Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Sit Investment Associates sold 150,175 BioCryst Pharmaceuticals shares in Q1 2016, an estimated $1.55M.
  • Sit Investment Associates first reported a position in BioCryst Pharmaceuticals in Q4 2014 and held it in 5 quarters.
  • Sit Investment Associates's BioCryst Pharmaceuticals position peaked at $1.8M in Q2 2015.
  • 109 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2016.

Based on Sit Investment Associates's 13F filing for Q1 2016, filed 14 Apr 2016.